重症监护病房收治的COVID-19患者血流感染的特征与预后:COVID-ICU研究的辅助分析
本研究为多中心前瞻性国际队列研究(COVID-ICU研究)的辅助分析,纳入4010例COVID-19 ICU患者,其中780例(19.5%)发生1066次血流感染(每1000患者风险日10.3次),92%在ICU获得。采用Fine和Gray竞争风险模型分析危险因素,并用倾向性评分匹配537例血流感染患者与537例对照比较预后。结果示较高的SAPS II、男性、入院至ICU时间较长及入院前使用抗病毒药物与血流感染风险独立相关,且风险随时间下降;血流感染与总体人群死亡时间缩短独立相关(aHR 1.28,95%CI 1.05-1.56),匹配后血流感染组病死率39% vs 对照组33%(P=0.036)。血流感染占总体人群死亡的3.6%。
要点
- 4010例COVID-19 ICU患者中780例(19.5%)发生血流感染,共1066次,每1000患者风险日10.3次,其中92%在ICU获得。
- 较高的SAPS II、男性、入院至ICU时间较长及入院前使用抗病毒药物与血流感染风险独立相关,风险随时间下降。
- 血流感染与总体人群死亡时间缩短独立相关(aHR 1.28,95%CI 1.05-1.56)。
- 倾向性评分匹配后,血流感染组病死率39% vs 对照组33%(P=0.036)。
- 血流感染占总体人群死亡的3.6%。
适用人群与场景
- 多中心前瞻性国际队列研究(COVID-ICU研究)纳入的4010例COVID-19 ICU患者;本分析仅纳入具有主要结局(入ICU后90天内死亡)或血流感染状态数据的患者。
研究设计与关键结果
- 研究类型为多中心前瞻性国际队列研究(COVID-ICU研究)的辅助分析,纳入4010例COVID-19 ICU患者。
- 780例(19.5%)发生1066次血流感染,发生率为每1000患者风险日10.3次,其中92%在ICU获得。
- 较高的SAPS II、男性、入院至ICU时间较长及入院前使用抗病毒药物与血流感染风险升高独立相关,且风险随时间下降。
- 血流感染与总体人群死亡时间缩短独立相关(aHR 1.28,95%CI 1.05-1.56)。
- 倾向性评分匹配537例血流感染患者与537例对照,血流感染组病死率39% vs 对照组33%(P=0.036)。
- 血流感染占总体人群死亡的3.6%。
证据类型、等级与局限
- 证据类型:多中心前瞻性国际队列研究(COVID-ICU研究)的辅助分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- COVID-19 ICU患者血流感染风险高,尤其在入ICU早期,风险随病情严重程度增加而升高,但与使用皮质激素无关。
- 血流感染与病死率升高相关,提示临床需关注COVID-19 ICU患者的血流感染监测与防治。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-COV 2) and requiring intensive care unit (ICU) have a high incidence of hospital-acquired infections; however, data regarding hospital acquired bloodstream infections (BSI) are scarce. We aimed to investigate risk factors and outcome of BSI in critically ill coronavirus infectious disease-19 (COVID-19) patients.
PATIENTS AND METHODS: We performed an ancillary analysis of a multicenter prospective international cohort study (COVID-ICU study) that included 4010 COVID-19 ICU patients. For the present analysis, only those with data regarding primary outcome (death within 90 days from admission) or BSI status were included. Risk factors for BSI were analyzed using Fine and Gray competing risk model. Then, for outcome comparison, 537 BSI-patients were matched with 537 controls using propensity score matching.
RESULTS: Among 4010 included patients, 780 (19.5%) acquired a total of 1066 BSI (10.3 BSI per 1000 patients days at risk) of whom 92% were acquired in the ICU. Higher SAPS II, male gender, longer time from hospital to ICU admission and antiviral drug before admission were independently associated with an increased risk of BSI, and interestingly, this risk decreased over time. BSI was independently associated with a shorter time to death in the overall population (adjusted hazard ratio (aHR) 1.28, 95% CI 1.05-1.56) and, in the propensity score matched data set, patients with BSI had a higher mortality rate (39% vs 33% p = 0.036). BSI accounted for 3.6% of the death of the overall population.
CONCLUSION: COVID-19 ICU patients have a high risk of BSI, especially early after ICU admission, risk that increases with severity but not with corticosteroids use. BSI is associated with an increased mortality rate.
参考来源
- Massart N, Maxime V, Fillatre P, et al. Characteristics and prognosis of bloodstream infection in patients with COVID-19 admitted in the ICU: an ancillary study of the COVID-ICU study. Ann Intensive Care. 2021. PMID: 34952960. doi:10.1186/s13613-021-00971-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。